Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

Abstract Background In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease progression. However, nintedanib was n...

Full description

Bibliographic Details
Main Authors: Michael Kreuter, Wim A. Wuyts, Marlies Wijsenbeek, Sabrina Bajwah, Toby M. Maher, Susanne Stowasser, Natalia Male, Wibke Stansen, Nils Schoof, Leticia Orsatti, Jeffrey Swigris
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Respiratory Research
Subjects:
SGRQ
UCSD-SOBQ
CASA-Q
EQ-5D VAS
Online Access:https://doi.org/10.1186/s12931-020-1298-1

Internet

https://doi.org/10.1186/s12931-020-1298-1

Similar Items